TLDR ARK Invest sold 39,362 Bullish (BLSH) shares worth ~$1.56 million on March 23, spread across ARKK and ARKW ETFs BLSH stock rose 4.16% on the day ARK sold,TLDR ARK Invest sold 39,362 Bullish (BLSH) shares worth ~$1.56 million on March 23, spread across ARKK and ARKW ETFs BLSH stock rose 4.16% on the day ARK sold,

Bullish (BLSH) Stock Climbs 4% As Cathie Wood Cashes Out

2026/03/24 18:10
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • ARK Invest sold 39,362 Bullish (BLSH) shares worth ~$1.56 million on March 23, spread across ARKK and ARKW ETFs
  • BLSH stock rose 4.16% on the day ARK sold, closing around $39.55
  • ARK had already sold 103,379 BLSH shares worth ~$3.93 million on March 20
  • Despite the recent selling, ARK bought roughly 2.1 million BLSH shares worth ~$58–$60 million over nine days in February 2026
  • Analysts have a Moderate Buy consensus on BLSH with an average price target of $47.83, implying ~20.9% upside

Cathie Wood’s ARK Invest sold a combined 39,362 Bullish (BLSH) shares on Monday, March 23, worth roughly $1.56 million, even as the stock climbed 4.16% that day.


BLSH Stock Card
Bullish, BLSH

The sales came through two ETFs: ARK Innovation ETF (ARKK) offloaded 31,154 shares, while ARK Next Generation Internet ETF (ARKW) sold 8,208 shares. BLSH’s last closing price was $39.55.

This wasn’t a one-off move. Just three days earlier, on March 20, ARK had already cut 103,379 BLSH shares for around $3.93 million — a larger sale that flew under the radar compared to Monday’s action.

The two-day total comes to 142,741 shares sold, valued at roughly $5.5 million combined. For context, ARK holds a position built up over months of aggressive buying.

In February 2026, ARK went on a nine-day buying spree in BLSH, picking up approximately 2.1 million shares for around $58–$60 million. Those purchases came in the wake of a post-earnings pullback in the stock.

What the Numbers Say

Bullish reported fourth-quarter 2025 adjusted revenue of $92.5 million and adjusted EBITDA of $44.5 million, both up year-over-year. Net loss widened to $563.6 million, though adjusted net income improved to $28.9 million.

Digital asset sales came in at $64.3 billion for the quarter, a slight dip. The company guided for 2026 subscription, services, and other revenue of $220 million to $250 million.

Adjusted operating expenses are expected to land between $210 million and $230 million for the full year.

Why ARK Is Trimming

The recent selling looks more tactical than a change in conviction. ARK Invest has historically bought BLSH during pullbacks and trimmed on price strength — Monday’s sale neatly fits that pattern, with the stock up over 4% on the day.

ARK is also rotating some capital into biotech. On Monday, the firm added 98,722 shares of 10X Genomics (TXG) for $1.89 million, even as TXG was also up 4.08% that day.

Crypto-linked names like BLSH tend to move sharply with Bitcoin prices and regulatory news, making them natural candidates for partial profit-taking after a strong run.

On TipRanks, BLSH carries a Moderate Buy consensus based on four Buy ratings and two Hold ratings. The average analyst price target sits at $47.83, implying roughly 20.9% upside from current levels.

The post Bullish (BLSH) Stock Climbs 4% As Cathie Wood Cashes Out appeared first on CoinCentral.

Market Opportunity
ARK Logo
ARK Price(ARK)
$0.1712
$0.1712$0.1712
+0.29%
USD
ARK (ARK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.